All-Time M&A Record for Life Sciences in 2019

Life sciences mergers and acquisitions (M&A) activity, driven by pharmaceutical buyers, totaled an unprecedented US$357b in 2019 (as of 30 November), breaking the 2014 record. Medical technology and biotechnology companies remained on the sidelines, showing life sciences companies did not use their firepower equally. This is according to the 2020 EY M&A Firepower report, launched today. The EY report finds that acute growth gaps (difference between a company’s revenue growth and the overall industry’s sales expansion) and a volatile market created significant opportunities in 2019, including four megamergers worth a combined US$231b. The forces driving 2019 M&A activity will continue to push deals in 2020, as companies optimize portfolios to deepen therapy area focus, seek to increase near-term revenue and use novel deal structures to access innovation.

Read the full article: All-Time M&A Record for Life Sciences in 2019 //


Scroll to Top